GE Healthcare Licenses Cellomics Core IP For High-Content Screening Methods | GenomeWeb

Not resting on its laurels following its April acquisition of Amersham, GE Healthcare has made a series of strategic moves to quickly strengthen the presence of its biosciences unit in the high-content screening and drug discovery market.

The most recent of these came last Tuesday when HCS innovator Cellomics non-exclusively licensed its core HCS patent portfolio to GE Healthcare and granted rights to GE to sublicense the same technologies to pharmaceutical customers. Financial terms of the deal were not disclosed.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.